Live Blogging Trials from Conferences — NephJC An interview about our experiment with conference coverage of simultaneously published studies

Do you have #FOMO from missing all the fun at #ISNWCN ?
We've got you covered!!
Check out the interview with
@nephroseeker.medsky.social and @hswapnil.medsky.social
discussing simultaneous publications at WCN in Yokohama, Japan #NephSky
www.nephjc.com/news/conf-coverage

Hiponatremia: El Resumen Visual — NephJC La hiponatremia es uno de los trastornos electrolíticos más frecuentes en pacientes hospitalizados y se asocia de manera consistente con peores desenlaces. Su corrección mejora los valores, pero ¿real...

Hiponatremia el resumen visual, gracias @dramiliflores.bsky.social #NephSky #NephJC

www.nephjc.com/news/2026/4/4/hiponatremia-el-resumen-visual

Hyponatremia Correction: The Visual Abstract — NephJC Hyponatremia is one of the most common electrolyte disorders in hospitalized patients and is consistently linked to worse outcomes. Correcting sodium improves the numbers—but does it improve short-ter...

📉Low asymptomatic sodium in a hospitalized patient:
Are you chill 🧊 or do you treat 🛠️ ?
Next #NephJC 4/7/26, we're changing it up (let's see if anyone notices 👀) #NephSky
VA by @brianrifkin.bsky.social
www.nephjc.com/news/2026/4/4/hyponatremia-correction-the-visual-abstract

UW Nephrology women faculty and fellows group photo.

What a great turnout for our Spring WIN-Women in #Nephrology gathering! Many thanks to Dr. Leah Haseley for hosting & Dr. Laura Mayeda for organizing the event. Shout-out to our amazing fellows and faculty women of UW Nephrology @uwnephrology.bsky.social @uwmedicine.bsky.social #nephsky #kidneydocs

Evolving Methods, Changing Attitudes Usher in a New Era in CKD Research | Docwire News Hiddo Heerspink, PhD, discusses how shifts in trial design, methodology, and regulatory attitudes are helping to advance chronic kidney disease (CKD) research.

🔗 www.docwirenews.com/post/evolvin...
Prof. Hiddo Heerspink spoke with us about how changing trial designs, methodologies, and regulatory attitudes are ushering in a new era for #CKD research. #nephsky #nephrology #clinicaltrials #kidneydisease

NephJC Short: The Push Trial — NephJC Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?

🚨 #NephJC short 🩳from @kidneyboy.bsky.social
The PUSH trial!
😉Can a wink, a nudge & a push encourage kidney stone formers to drink more fluid to prevent recurrence 🪨?
(Hint: have 💦 behavioral trials worked in CHF or PCKD?)
#NephSky #MedSky
www.nephjc.com/news/2026/4/2/nephjc-short-the-push-trial

🤝 Looking for interactive learning at #NKFClinicals? Our SCM26 Workshops offer hands-on discussions and practical strategies you can bring back to your practice.

📍 Explore the workshop schedule: bit.ly/4qfRVHd

#Nephrology #MedEd #KidneyCare #NephSky

The study suggests doctors should test for HTRA1 in older patients when standard tests don't find a cause, since identifying the actual problem helps determine the right treatment. #renalpath #nephsky #pathsky

Framework for Apolipoprotein 1-Mediated Kidney Disease Classification Black Americans have an increased risk of chronic kidney disease (CKD) compared with individuals without African ancestry. Variants designated G1 and G2 in the apolipoprotein L1 protein encoded by the APOL1 gene are a major contributor to this increased risk.1 These variants arose independently, rar...

We're excited to share a new research publication from Dr. Jon Wilson, @glombandit.bsky.social, Dr. Randy Haun, and Dr. Chris Larsen titled "Framework for Apolipoprotein 1-Mediated Kidney Disease Classification."

Read here: www.kireports.org/article/S2468-0249(26)02...

#nephsky

Cats want a recount! 🐈🐈🐈
What about mail-in ballots and hanging chads?
This is a cat-astrophe. I’m cat-atonic with rage.
#NephMadness #BlueRibbonFail
Cats rule and dogs drool! #NephSky

Transplant bx for renal dysfunction in a patient with shortness of breath. Granulomatous tubulointerstitial nephritis. AFB stain +. Sputum + for TB. Good sample key for making the diagnosis. 2 rounds of AFB stain to find the organism. #renalpath #pathksy #nephsky

a cartoon character says i 'm so confused in front of a futurama logo ALT: a cartoon character says i 'm so confused in front of a futurama logo

Effluent 8 are in 🔥 #NephMadness

New B-Cell 🎯
Natural Language 💻
@Dog4NephMadness
🦠BKV
C3G
🧠Nephrology in ESKD
#pocus in AKI
PKD Masqueraders

The Blue Ribbon Panel is on the move 👀 @nephmadness.bsky.social #nephsky #medsky

Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence The therapeutic landscape of IgA nephropathy (IgAN) has evolved rapidly. The renaissance for the treatment of IgAN began with the development of nefecon, targeted-release budesonide (TRF-budesonide; T...

Also see: editorial from Heather Reich and @kdjhaveri.bsky.social in @kireports.bsky.social synthesizing the data on enteric coated budesonide

www.kireports.org/article/S246...

Nothing special about Nefecon IMO (like ACTHAR!)

#NephSky

Renal Physicians Association Annual Meeting: Q&A With the Program Chair | Docwire News Nephrology Times spoke to Katherine Kwon, program chair of the Renal Physicians Association 2026 Annual Meeting, about what the event offers nephrology professionals.

🔗 www.docwirenews.com/post/renal-p...
Attending the Renal Physicians Association Annual Meeting later this month? in this Q&A, program chair Dr. Katherine Kwon explains why it's one you don't want to miss. #nephrology #nephsky

Simplifying the Approach to Primary Aldosteronism • Review the pathophysiology of primary aldosteronism (PA). • Demonstrate that PA is common, and can be found in patients across the entire spectrum of hypertension. • Show th

Please consider joining me on Friday, Apr 10 at 3PM EST for this webinar on Simplifying the Approach to Primary Aldosteronism. #nephsky #htn
www.labroots.com/webinar/simp...

🔗 www.docwirenews.com/journal/apri...
NO FOOLING ... Our April issue is here, featuring AI in kidney care, a Q&A with the new president of ANNA, research updates, and much more. #nephrology #nephsky

The most classic #nephsky #nephmadness month of all is here…. & coincidentally, the most popular pick for @nephmadness.bsky.social champion is in fact, B-cell targets… over 400 brackets!, 🤓😃😅🙏
cc: @lauraratcliffe7.bsky.social

This is no April Fool's joke - SCM26 is 35 days away! 😧

Join us in New Orleans for the latest in nephrology! Register today, with added value available for NKF Professional Members!

Secure your spot: bit.ly/4j9Nxa0

#NKFClinicals #Nephrology #KidneyHealth #NephSky

🚨🚨🚨It is official!!!
Team Cat 🐈 has just won #NephMadness 2026 in the greatest upset of all time!!!
#NephSky

(April Fools)

WCN26-2413 SYNERGISTIC EFFECTS OF TRF-BUDESONID AND SPARSENTAN IN IGA-NEPHROPATHY Sparsentan has emerged as a promising therapeutic option for IgA nephropathy (IgAN) while Targeted-release formulation (Trf-) Budesonid is an established treatment for patients with persistent protein...

This is not at all surprising, and it lends support for other combination therapies that have different mechanisms of action and targets. www.kireports.org/article/S246...

#NephSky #IgANephropathy #IgAN

What Did FDA Find? After reviewing postmarketing data from the applicant's submission (cases from their global safety database), the literature, and the FDA Adverse Event Reporting System (FAERS) database, which has been incorporated into the FDA Adverse Event Monitoring System (AEMS) database, through October 9, 2024, FDA identified 76 cases of DILI with reasonable evidence of a causal association with avacopan use. A total of 74 cases reported a serious outcome, including hospitalization (n=54) and death (n=8). A total of 60 cases provided laboratory information to determine the initial pattern of liver injury; the majority (n=38) had a cholestatic or mixed pattern often marked by substantial elevations in ALP and total bilirubin. A total of 73 cases provided In time from avacopan initiation to DILI onset, and the median time-to-onset was 46 days (range 22 to 140 days). Most cases (n=66) were reported from Japan, followed by the United States (n=5), Europe (n=4), and Canada (n=1). Of the 76 cases, 7 reported biopsy-confirmed VBDS as a complication of DILI with reasonable evidence of a causal association with avacopan use. All cases reported hospitalization (n=7), of which 3 had a fatal outcome. The initial pattern of liver injury was cholestatic or mixed in 4 cases and hepatocellular in 3 cases. The median time from avacopan initiation to DILI onset among the 7 cases was 46 days (range 33 to 59 days). Cases were reported from Japan (n=6) and Canada (n=1). FDA is continuing to monitor postmarketing cases of DILI, including VBDS, involving avacopan and will provide updates as appropriate

More badness uncovered here - today’s FDA warning

Some fatal case of DLI and several VBDS
They are recommending more frequent LFTs while starting Avacopan

www.fda.gov/media/191708...

This does not look good!

#NephSky

Need a place to stay for SCM26? Book your reservation at the Sheraton New Orleans or New Orleans Marriott - now with more rooms available!

Learn more about SCM and the available hotels here: www.kidney.org/spring-clini...

#NKFClinicals #NephSky

Shankland Lab members

The UW Department of Medicine, Division of #Nephrology, has an outstanding opportunity for a full-time, temporary Research Consultant in the highly regarded Shankland Lab!! 🔬 🫘 #research #kidneys #nephsky
@uwdeptmedicine.bsky.social

wd5.myworkdaysite.com/recruiting/u...

#MarchMadness #Nephsky

Conventional cytotoxic chemotherapy-associated nephrotoxicity The sub-field of onco-nephrology has rapidly grown with the proliferation of highly effective cancer therapies and the remarkable improvement in patient survival. Conventional cytotoxic chemotherapy…

Conventional cytotoxic chemotherapy-associated nephrotoxicity
#nephsky

#NephMaddness #NephSky Are you ready for some #BleRibbonFail 😂😂😂

NephJC Covers LBCTs at the World Congress — NephJC The NephJC editors cover the simultaneous publication from the world congress

Covering the world 🌐 @hswapnil.medsky.social @nephroseeker.medsky.social
🧑‍💻Reporting in from Yokohama, Japan #ISNWCN 🌸
📰Read all about the late breaking news #NephJC #NephSky
www.nephjc.com/news/isnwcn-yokohama

Techniques to predict survival outcomes in nephrology: basics and traditional methods Predicting survival outcomes is one of the most crucial tasks that nephrologists face. On an individual level, predicted survival times affect all aspects of decision-making, including the initiation…

Techniques to predict survival outcomes in nephrology: basics and traditional methods
#nephsky
#biostats

Did you know that the “four-hit” hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/21949093/

Reduced podocyte stiffness is a feature of proteinuric kidney disease Proteinuria is a common and important manifestation of glomerular injury. Although the molecular events driving proteinuria have been studied extensively, the biomechanical changes that occur in the…

Reduced podocyte stiffness is a feature of proteinuric kidney disease
#nephsky